The main purpose of this study is to determine the electrophysiological effects of cholinergic therapy (cholinesterase inhibitors and transdermal nicotine) in Alzheimer disease. The attempt will be to locate electrophysiological markers and predictors of cognitive and clinical treatment response...
Date First Received: July 3, 2001
Last Updated: June 23, 2005
Verified by: Department of Veterans Affairs, December 2004
Clinical Trial Phase: Phase 4 | Start Date: October 1998
Overall Status: Completed
Brief Summary
Official Title: “Verbal Memory ERPs as Indices of Treatment Response in Alzheimer Disease”
Condition Keyword(s):
Intervention(s):
The main purpose of this study is to determine the electrophysiological effects of cholinergic therapy (cholinesterase inhibitors and transdermal nicotine) in Alzheimer disease. The attempt will be to locate electrophysiological markers and predictors of cognitive and clinical treatment response.
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Crossover Assignment, Efficacy Study
Intervention(s) in this Clinical Trial
- Drug: Aricept
- Drug: Exelon
- Drug: Nicoderm Patch
Criteria for Participation in this Clinical Trial
- Patients diagnosed with mild to moderate probable Alzheimer's disease (mini-mental state exam scores between 15-27), and normal controls (age generally between 60-85). Subjects must either be planning to start daily cholinesterase therapy (e.g. Aricept, Exelon) or willing to try a transdermal nicotine patch for two 8 hour periods.
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 55 Years
Maximum Age for this Clinical Trial: 85 Years
Are Healthy Volunteers Accepted for this Clinical Trial?: Accepts Healthy Volunteers
Clinical Trial Sponsor Information
Lead Sponsor: Department of Veterans Affairs
Overall Clinical Trial Officials and Contacts
Vincente Iragui, M.D., Ph.D
Additional Information
Information obtained from ClinicalTrials.gov on October 07, 2008
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00018278
Study ID Number: AGCG-004-98S
ClinicalTrials.gov Identifier: NCT00018278
Health Authority: United States: Federal Government
Clinical Trials Authorship and Review
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
